Use of mixture of sodium hyaluronate and chondroitin sulfate for use in products and therapies for cosmetic surgery

Abstract

This invention is related to the use of a composition formed by sodium hyaluronate, sodium chondroitin sulfate and botulinum toxin type A for the treatment of dermal lines, and to the use of such composition in the manufacture of a product for such treatment.

1 . A therapeutic method for reducing dermal lines comprising the subdermal administration in a region associated with the dermal lines of a viscous composition comprising a therapeutically effective amount of a mixture of chondroitin sulfate, hyaluronic acid or pharmaceutically acceptable salts thereof and  botulinum  toxin type A.  
   
   
       2 . The method of  claim 1 , wherein the dermal lines are on a human patient and the dermal lines are caused by age or exposure .  
   
   
       3 . The method of either  claim 1  or  claim 2 , wherein the composition comprises a mixture of chondroitin sulfate at a concentration of 0.1 to 50% by weight and sodium hyaluronate at a concentration of 0.1 to 50% by weight.  
   
   
       4 . The method of  claim 3 , wherein the chondroitin sulfate concentration is from 0.1 to 5.3% by weight and the sodium hyaluronate concentration is from 0.1 to 4.2% by weight of the composition.  
   
   
       5 . The method of  claim 4 , wherein the composition is a sterile, non-pyrogenic, viscoelastic solution comprising a mixture of chondroitin sulfate and sodium hyaluronate in a ratio of about 4 parts by weight chondroitin sulfate to about 3 parts by weight sodium hyaluronate.  
   
   
       6 . The method of  claim 5 , wherein the concentration of chondroitin sulfate is about 40 mg/ml and the concentration of sodium hyaluronate is about 30 mg/ml.  
   
   
       7 . The method of  claim 6 , wherein the chondroitin sulfate has a molecular weight of 20,000 to 50,000 daltons, the sodium hyaluronate has a molecular weight of 500,000 to 1,000,000 daltons, and the composition has a viscosity of 20,000 to 60,000 cps.  
   
   
       8 . The method of  claim 1 , wherein doses of between 0.5 and 1.5 cubic centimeters of the viscoelastic composition are periodically administered to the associated region.  
   
   
       9 . The use of stable, viscous, buffered aqueous solution which comprises a mixture of chondroitin sulfate at a concentration of about 0.1 to 50% by weight, sodium hyaluronate at a concentration of about 0.1 to 50% by weight, and a therapeutically effective amount of  botulinum  toxin type A in the manufacture of a product for the subdermal treatment of dermal lines.  
   
   
       10 . The use according to  claim 9 , wherein said solution is maintained at a pH of about 7.0 to 8.0.  
   
   
       11 . The use according to  claim 9 , wherein the solution has an osmolarity of from about 300 to about 350 mOsmol/kg.